Selected research
Industry Research
Biologics and Biosimilars Industry Research Report 2026
Market perspective
The global Biologics and Biosimilars market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Biologics and Biosimilars market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Biologics and Biosimilars market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Biologics and Biosimilars market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Biologics and Biosimilars include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Pfizer, AbbVie, United Laboratory and Tonghua Dongbao, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Biologics and Biosimilars market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Biologics and Biosimilars.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biologics and Biosimilars Market by Company
Sanofi
Johnson & Johnson
Novartis
Merck
Roche
Pfizer
AbbVie
United Laboratory
Tonghua Dongbao
Sobi
Novo Nordisk
Kanghong Pharma
Innovent Biologics
Gan&Lee
Eli Lilly
Changchun High Tech
Celltrion
Biogen
Amgen
3SBIO
Biologics and Biosimilars Segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Biologics and Biosimilars Segment by Application
Hospital
Retail Pharmacy
Other
Biologics and Biosimilars Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biologics and Biosimilars companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monoclonal Antibodies
- Interferon
- Insulin
- Vaccines
- Others
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Sanofi
- Johnson & Johnson
- Novartis
- Merck
- Roche
- Pfizer
- AbbVie
- United Laboratory
- Tonghua Dongbao
- Sobi
- Novo Nordisk
- Kanghong Pharma
- Innovent Biologics
- Gan&Lee
- Eli Lilly
- Changchun High Tech
- Celltrion
- Biogen
- Amgen
- 3SBIO
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Biologics and Biosimilars by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Monoclonal Antibodies
- 2.2.3 Interferon
- 2.2.4 Insulin
- 2.2.5 Vaccines
- 2.2.6 Others
- 2.3 Biologics and Biosimilars by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Biologics and Biosimilars Breakdown Data by Type
- 3.1 Global Biologics and Biosimilars Historic Market Size by Type (2021-2026)
- 3.2 Global Biologics and Biosimilars Forecasted Market Size by Type (2027-2032)
4 Biologics and Biosimilars Breakdown Data by Application
- 4.1 Global Biologics and Biosimilars Historic Market Size by Application (2021-2026)
- 4.2 Global Biologics and Biosimilars Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Biologics and Biosimilars Market Perspective (2021-2032)
- 5.2 Global Biologics and Biosimilars Growth Trends by Region
- 5.2.1 Global Biologics and Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Biologics and Biosimilars Historic Market Size by Region (2021-2026)
- 5.2.3 Biologics and Biosimilars Forecasted Market Size by Region (2027-2032)
- 5.3 Biologics and Biosimilars Market Dynamics
- 5.3.1 Biologics and Biosimilars Industry Trends
- 5.3.2 Biologics and Biosimilars Market Drivers
- 5.3.3 Biologics and Biosimilars Market Challenges
- 5.3.4 Biologics and Biosimilars Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Biologics and Biosimilars Players by Revenue
- 6.1.1 Global Top Biologics and Biosimilars Players by Revenue (2021-2026)
- 6.1.2 Global Biologics and Biosimilars Revenue Market Share by Players (2021-2026)
- 6.2 Global Biologics and Biosimilars Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Biologics and Biosimilars Head Office and Area Served
- 6.4 Global Biologics and Biosimilars Players, Product Type & Application
- 6.5 Global Biologics and Biosimilars Manufacturers Established Date
- 6.6 Global Biologics and Biosimilars Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Biologics and Biosimilars Market Size (2021-2032)
- 7.2 North America Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Biologics and Biosimilars Market Size by Country (2021-2026)
- 7.4 North America Biologics and Biosimilars Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Biologics and Biosimilars Market Size (2021-2032)
- 8.2 Europe Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Biologics and Biosimilars Market Size by Country (2021-2026)
- 8.4 Europe Biologics and Biosimilars Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Biologics and Biosimilars Market Size (2021-2032)
- 9.2 Asia-Pacific Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Biologics and Biosimilars Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Biologics and Biosimilars Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Biologics and Biosimilars Market Size (2021-2032)
- 10.2 South America Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Biologics and Biosimilars Market Size by Country (2021-2026)
- 10.4 South America Biologics and Biosimilars Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Biologics and Biosimilars Market Size (2021-2032)
- 11.2 Middle East & Africa Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Biologics and Biosimilars Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Biologics and Biosimilars Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi
- 12.1.1 Sanofi Company Information
- 12.1.2 Sanofi Business Overview
- 12.1.3 Sanofi Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.1.4 Sanofi Biologics and Biosimilars Product Portfolio
- 12.1.5 Sanofi Recent Developments
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Company Information
- 12.2.2 Johnson & Johnson Business Overview
- 12.2.3 Johnson & Johnson Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.2.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
- 12.2.5 Johnson & Johnson Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.3.4 Novartis Biologics and Biosimilars Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Merck
- 12.4.1 Merck Company Information
- 12.4.2 Merck Business Overview
- 12.4.3 Merck Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.4.4 Merck Biologics and Biosimilars Product Portfolio
- 12.4.5 Merck Recent Developments
- 12.5 Roche
- 12.5.1 Roche Company Information
- 12.5.2 Roche Business Overview
- 12.5.3 Roche Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.5.4 Roche Biologics and Biosimilars Product Portfolio
- 12.5.5 Roche Recent Developments
- 12.6 Pfizer
- 12.6.1 Pfizer Company Information
- 12.6.2 Pfizer Business Overview
- 12.6.3 Pfizer Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.6.4 Pfizer Biologics and Biosimilars Product Portfolio
- 12.6.5 Pfizer Recent Developments
- 12.7 AbbVie
- 12.7.1 AbbVie Company Information
- 12.7.2 AbbVie Business Overview
- 12.7.3 AbbVie Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.7.4 AbbVie Biologics and Biosimilars Product Portfolio
- 12.7.5 AbbVie Recent Developments
- 12.8 United Laboratory
- 12.8.1 United Laboratory Company Information
- 12.8.2 United Laboratory Business Overview
- 12.8.3 United Laboratory Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.8.4 United Laboratory Biologics and Biosimilars Product Portfolio
- 12.8.5 United Laboratory Recent Developments
- 12.9 Tonghua Dongbao
- 12.9.1 Tonghua Dongbao Company Information
- 12.9.2 Tonghua Dongbao Business Overview
- 12.9.3 Tonghua Dongbao Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.9.4 Tonghua Dongbao Biologics and Biosimilars Product Portfolio
- 12.9.5 Tonghua Dongbao Recent Developments
- 12.10 Sobi
- 12.10.1 Sobi Company Information
- 12.10.2 Sobi Business Overview
- 12.10.3 Sobi Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.10.4 Sobi Biologics and Biosimilars Product Portfolio
- 12.10.5 Sobi Recent Developments
- 12.11 Novo Nordisk
- 12.11.1 Novo Nordisk Company Information
- 12.11.2 Novo Nordisk Business Overview
- 12.11.3 Novo Nordisk Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.11.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
- 12.11.5 Novo Nordisk Recent Developments
- 12.12 Kanghong Pharma
- 12.12.1 Kanghong Pharma Company Information
- 12.12.2 Kanghong Pharma Business Overview
- 12.12.3 Kanghong Pharma Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.12.4 Kanghong Pharma Biologics and Biosimilars Product Portfolio
- 12.12.5 Kanghong Pharma Recent Developments
- 12.13 Innovent Biologics
- 12.13.1 Innovent Biologics Company Information
- 12.13.2 Innovent Biologics Business Overview
- 12.13.3 Innovent Biologics Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.13.4 Innovent Biologics Biologics and Biosimilars Product Portfolio
- 12.13.5 Innovent Biologics Recent Developments
- 12.14 Gan&Lee
- 12.14.1 Gan&Lee Company Information
- 12.14.2 Gan&Lee Business Overview
- 12.14.3 Gan&Lee Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.14.4 Gan&Lee Biologics and Biosimilars Product Portfolio
- 12.14.5 Gan&Lee Recent Developments
- 12.15 Eli Lilly
- 12.15.1 Eli Lilly Company Information
- 12.15.2 Eli Lilly Business Overview
- 12.15.3 Eli Lilly Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.15.4 Eli Lilly Biologics and Biosimilars Product Portfolio
- 12.15.5 Eli Lilly Recent Developments
- 12.16 Changchun High Tech
- 12.16.1 Changchun High Tech Company Information
- 12.16.2 Changchun High Tech Business Overview
- 12.16.3 Changchun High Tech Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.16.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
- 12.16.5 Changchun High Tech Recent Developments
- 12.17 Celltrion
- 12.17.1 Celltrion Company Information
- 12.17.2 Celltrion Business Overview
- 12.17.3 Celltrion Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.17.4 Celltrion Biologics and Biosimilars Product Portfolio
- 12.17.5 Celltrion Recent Developments
- 12.18 Biogen
- 12.18.1 Biogen Company Information
- 12.18.2 Biogen Business Overview
- 12.18.3 Biogen Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.18.4 Biogen Biologics and Biosimilars Product Portfolio
- 12.18.5 Biogen Recent Developments
- 12.19 Amgen
- 12.19.1 Amgen Company Information
- 12.19.2 Amgen Business Overview
- 12.19.3 Amgen Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.19.4 Amgen Biologics and Biosimilars Product Portfolio
- 12.19.5 Amgen Recent Developments
- 12.20 3SBIO
- 12.20.1 3SBIO Company Information
- 12.20.2 3SBIO Business Overview
- 12.20.3 3SBIO Revenue in Biologics and Biosimilars Business (2021-2026)
- 12.20.4 3SBIO Biologics and Biosimilars Product Portfolio
- 12.20.5 3SBIO Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst